Casi Pharmaceuticals Inc (CASI)

Jan 6, 2025, 8:00 AM EST - 13 days ago

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

Nov 15, 2024, 8:00 AM EST - 2 months ago

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

Oct 24, 2024, 8:00 AM EDT - 3 months ago

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

Sep 4, 2024, 8:00 AM EDT - 4 months ago

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

Aug 16, 2024, 8:00 AM EDT - 5 months ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

Jul 19, 2024, 5:30 PM EDT - 6 months ago

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Jul 8, 2024, 7:30 AM EDT - 6 months ago

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

Jun 26, 2024, 4:15 PM EDT - 7 months ago

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

Jun 26, 2024, 4:10 PM EDT - 7 months ago

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

May 15, 2024, 8:00 AM EDT - 8 months ago

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

May 14, 2024, 8:00 AM EDT - 8 months ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

Mar 28, 2024, 7:00 AM EDT - 10 months ago

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

Mar 5, 2024, 7:00 AM EST - 11 months ago

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China

Feb 16, 2024, 7:00 AM EST - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

Nov 14, 2023, 7:00 AM EST - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Nov 8, 2023, 7:00 AM EST - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

Aug 11, 2023, 7:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

Aug 1, 2023, 7:00 AM EDT - 1 year ago

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

Jul 20, 2023, 8:00 AM EDT - 1 year ago

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

Jul 20, 2023, 8:00 AM EDT - 1 year ago

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

May 17, 2023, 7:35 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

Apr 26, 2023, 9:49 AM EDT - 1 year ago

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

Apr 26, 2023, 7:00 AM EDT - 1 year ago

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

Mar 21, 2023, 4:30 PM EDT - 1 year ago

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

Jan 6, 2023, 8:42 AM EST - 2 years ago

Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China

Jan 6, 2023, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

Dec 15, 2022, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Nov 14, 2022, 7:00 AM EST - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

Sep 23, 2022, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

Sep 9, 2022, 10:32 AM EDT - 2 years ago

ALJ Regional Hldgs (NASDAQ:ALJJ), CASI Pharmaceuticals (NASDAQ:CASI) – $2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying

LDI TERN

Sep 7, 2022, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA

Aug 29, 2022, 8:58 AM EDT - 2 years ago

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

HCWB HSDT

Aug 12, 2022, 12:28 PM EDT - 2 years ago

CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q2 2022 Results - Earnings Call Transcript

Aug 12, 2022, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS

Aug 5, 2022, 8:38 AM EDT - 2 years ago

CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022

Jul 8, 2022, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION

Jun 2, 2022, 6:34 AM EDT - 2 years ago

CASI Pharmaceuticals stock falls after reverse split takes effect

May 26, 2022, 4:30 PM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT

May 24, 2022, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD

May 12, 2022, 11:32 AM EDT - 2 years ago

CASI Pharmaceuticals, Inc.'s (CASI) CEO Wei-Wu He on Q1 2022 Results - Earnings Call Transcript

May 12, 2022, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS

May 2, 2022, 7:00 AM EDT - 2 years ago

CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022

Apr 1, 2022, 2:31 PM EDT - 3 years ago

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

HCM ZLAB

Apr 1, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS STATEMENT ON STATUS UNDER HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT

Mar 28, 2022, 1:54 PM EDT - 3 years ago

CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q4 2021 Results - Earnings Call Transcript

Mar 28, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA® REVENUE

Mar 23, 2022, 7:00 AM EDT - 3 years ago

CASI PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS AND HOST CONFERENCE CALL MARCH 28, 2022

Mar 4, 2022, 7:00 AM EST - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES RENEWAL OF EXCLUSIVE DISTRIBUTION AGREEMENT FOR EVOMELA® IN CHINA

Feb 16, 2022, 7:00 AM EST - 3 years ago

CASI PHARMACEUTICALS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2021 REVENUES AND PROVIDES BUSINESS UPDATES

Jan 20, 2022, 7:00 AM EST - 3 years ago

CASI PHARMACEUTICALS PARTNER, BIOINVENT, ANNOUNCES BI -1206 GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA